Dr. Deborah I Haggett, ED.D, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 17 Red Oak Dr, Tabernacle, NJ 08088 Phone: 856-988-9727 Fax: 609-268-2573 |
News Archive
Researchers have shown that they can put mouse embryonic stem cells to work building the heart, potentially moving medical science a significant step closer to a new generation of heart disease treatments that use human stem cells.
Surveys of drug use form an important basis for the development of effective drug policies, and also for measuring the effectiveness of existing policies. For the first time in history, scientists have now made direct comparisons of illicit drug use in 19 European cities by a cooperative analysis of raw sewage samples.
In an effort to accelerate the control of malaria and help eliminate it worldwide, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced approximately $14 million in first-year funding to establish 10 new malaria research centers around the world.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.
› Verified 2 days ago